Jordi Remon, Thoracic oncologist at CIOCC Barcelona, shared a post on X:
“2024: Fortunately it is difficult to merge all treatments for Non-Small Cell Lung Cancer (NSCLC) in 1 slide.
Hwv, still pending:
- Avoid me too approvals if prices not.
- Consol TKI for all and for lifetime?
- Genotyping access and drug access.
- Academic trials of de-escalating periop vs neoadjuvant.”
More posts featuring Jordi Remon.